Cingulate Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Cingulate raised $31M in capital (private placement $12M + ATM/Lincoln Park $19M) in H1 2026, bringing cash to $28.4M (146% of current market cap), providing runway to mid-2027. FDA issued Complete Response Letter on June 1, 2026 for CTx-1301 NDA requesting additional CMC work; company plans resubmission as soon as practicable. Company signed distribution deal with Prasco (July 21, 2026) covering ~19,000 pharmacy accounts and obtained U.S. Patent 12,653,791 (June 16, 2026) protecting CTx-1301 through 2042; SG&A expenses increased 181.7% YoY to $9.7M in H1 2026 due to commercialization build-out.
Why this rating
Capital raised is 160% of company size, extending runway significantly. NDA rejection is setback but non-fatal; no efficacy/safety concerns noted. Patent grant and distribution deals represent tangible commercialization progress. High burn rate and binary FDA outcome present material execution risk.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.